May 21, 2020: PrEP demographics by health insurance claim data; pediatricians call for better PrEP formulations for teens; weight gain after switching from TDF to TAF; two-drug regimen efficacy when baseline viral load is high.
Giving good HIV care means taking into account the many marginalize identities patients can hold. And, being marginalized often comes with a lot of trauma.
March 26, 2020: Lopinavir/ritonavir falls short against COVID-19; impact of PrEP scale-up on HIV diagnoses; long-term cost-effectiveness of various HIV interventions; disparities in virologic suppression among young people.
Replacing group meetings and public outreach with telehealth consults, Zoom meet-ups, and food/med curbside deliveries are all part of the solutions.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Doctors contemplate the role of housing in health care as people with HIV grow older, but are often poor.
Feb. 13, 2020: PrEP's psychosocial benefits; supplementing ADAP with Obamacare plans; lack of HIV and HCV testing for people who inject drugs; frailty is more common, but not more deadly, in HIV settings.
Feb. 6, 2020: HIV medication costs outpace inflation; HIV's role in attenuating childhood vaccinations; the challenges of researching effects of medications during pregnancy; the need for localized HIV interventions in the U.S.
Jan. 30, 2020: Polypharmacy vs. drug interaction risk among people living with HIV as they age; cost-effectiveness of ibalizumab; PrEP persistence on Medicaid vs. private health coverage.
Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.